Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,633,855.85 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 19,315 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $84.59, for a total transaction of $1,633,855.85. Following the completion of the transaction, the chief executive officer owned 574,505 shares in the company, valued at approximately $48,597,377.95. This trade represents a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $79.73 on Friday. Protagonist Therapeutics, Inc. has a one year low of $33.70 and a one year high of $96.54. The company’s fifty day moving average price is $86.33 and its 200-day moving average price is $72.53. The firm has a market capitalization of $4.98 billion, a price-to-earnings ratio of 128.60 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The firm had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. BTIG Research restated a “buy” rating and issued a $82.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. Weiss Ratings raised Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. Barclays upped their target price on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Citigroup upped their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.77.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. American Century Companies Inc. increased its holdings in Protagonist Therapeutics by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock worth $44,990,000 after acquiring an additional 128,171 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in Protagonist Therapeutics during the second quarter valued at $6,641,000. Voya Investment Management LLC grew its position in shares of Protagonist Therapeutics by 8.9% during the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock valued at $20,289,000 after purchasing an additional 25,065 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in Protagonist Therapeutics during the 2nd quarter valued at approximately $7,464,000. Finally, Creative Planning grew its stake in shares of Protagonist Therapeutics by 74.3% in the 2nd quarter. Creative Planning now owns 30,204 shares of the company’s stock worth $1,669,000 after buying an additional 12,871 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.